Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2017

Feb 21, 2017

35334_dirs_2017-02-21_e59ec984-e805-4dc2-a467-6660eff3f489.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-02-16

Reporting Person: Springate Wayne S. (Sr VP of Operations)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-02-16 Common Stock P 8014 $0.46 Acquired 16641 Direct

Footnotes

F1: The amount of securities beneficially owned following the reported transaction was incorrect when filed earlier today (2/21/17).